Therapeutic Options in Other Metabolic Myopathies

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 579-582

  Vorgerd, Matthias ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

carnitine palmitoyltransferase (CPT) 2 deficiency; glycogen storage disease; lipid storage disease; McArdle disease; metabolic myopathy; rhabdomyolysis

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BEZAFIBRATE; BICARBONATE; CREATINE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GENTAMICIN; GLUCOSE; INFUSION FLUID; MANNITOL; RAMIPRIL; SUCROSE;

AEROBIC EXERCISE; ALKALINIZATION; ARTICLE; ARTIFICIAL VENTILATION; CARNITINE PALMITOYLTRANSFERASE 2 DEFICIENCY; DIET; ENZYME DEFICIENCY; GLYCOGEN STORAGE DISEASE TYPE 5; HEMOFILTRATION; HUMAN; LOW DRUG DOSE; METABOLIC MYOPATHY; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CREATINE; EXERCISE THERAPY; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; LIPID METABOLISM; METABOLIC DISEASES; MUSCULAR DISEASES; RHABDOMYOLYSIS;

EID: 53049090233     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.006     Document Type: Article

References (21)

1. Quinlivan R., and Vissing J. 144th ENMC International Workshop: outcome measures in McArdle disease. Neuromuscul Disord 17 (2007) 494-498
2. Quinlivan R., Beynon R.J., and Martinuzzi A. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst Rev 2 (2008) CD003458
3. Bonnefont J.P., Djouadi F., Prip-Buus C., Gobin S., Munnich A., and Bastin J. Carnitine palmitoyltransferase 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25 (2004) 495-520
4. Kley R.A., Vorgerd M., and Tarnopolsky M. Creatine for treating muscle disorders. Cochrane Database Syst Rev 1 (2007) CD004760
5. Willott C.A., Young M.E., Leighton B., et al. Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin. Acta Physiol Scand 166 (1999) 99-104
6. Vorgerd M., Grehl T., Jager M., et al. Creatine therapy in myophosphorylase deficiency (McArdle's disease): a placebo controlled crossover trial. Arch Neurol 57 (2000) 956-963
7. Vorgerd M., Zange J., Kley R., et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle's disease: double-blind, placebo-controlled crossover trial. Arch Neurol 59 (2002) 97-101
8. Andersen S.T., and Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effect on exercise capacity. J Neurol Neurosurg Psychiatry (2008) Jun 5; [Epub ahead of print]
9. Haller R.G., Wyrick M.A., Taivassalo T., and Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 59 (2006) 922-928
10. Martinuzzi A., Sartori E., Fanin M., et al. Phenoytype modulators in myophosphorylase deficiency. Ann Neurol 53 (2003) 497-502
11. Rubio J.C., Gómez-Gallego F., Santigao C., et al. Genotype modulators of clinical severity in McArdle disease. Neurosci Lett 422 (2007) 217-222
12. Martinuzzi A., Liava A., Trevisi E., et al. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle Nerve 37 (2008) 350-357
13. Schroers A., Kley R.A., Stachon A., et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 66 (2006) 285-286
14. Andersen S.T., Haller R.G., and Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 65 (2008) 786-789
15. Orngreen M.C., Olsen D.B., and Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology 59 (2002) 1046-1051
16. Orngreen M.C., Ejstrup R., and Vissing J. Effect of diet on exercise intolerance in carnitine palmitoyltransferase II deficiency. Neurology 61 (2003) 559-561
17. Djouadi F., Bonnefont J.P., Thuillier L., et al. Correction of fatty acid oxidation in carnitine palmitoyltransferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 54 (2003) 446-451
18. Djouadi F., Aubey F., Schlemmer D., and Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab 90 (2005) 1791-1797
19. Roe C.R., Sweetman L., Roe D.S., David F., and Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110 (2002) 259-269
20. Roe C.R., and Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 29 (2006) 332-340
21. Huerta-Alardin A.L., Varon J., and Marik P.E. Bench-to-bedside review: Rhabdomyolysis-an overview for clinicians. Crit Care 9 (2005) 158-169